PMC:7443692 / 3978-4221 JSONTXT

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T4","span":{"begin":75,"end":87},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A4","pred":"meddra_id","subj":"T4","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062026"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T25","span":{"begin":0,"end":243},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T17","span":{"begin":154,"end":163},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T403","span":{"begin":56,"end":60},"obj":"Protein"},{"id":"T404","span":{"begin":173,"end":177},"obj":"Protein"}],"attributes":[{"id":"A403","pred":"uniprot_id","subj":"T403","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A404","pred":"uniprot_id","subj":"T404","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T26","span":{"begin":154,"end":163},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}

{"project":"2_test","denotations":[{"id":"32841605-32332765-19659471","span":{"begin":215,"end":219},"obj":"32332765"},{"id":"32841605-32333836-19659472","span":{"begin":237,"end":241},"obj":"32333836"}],"text":"In similar fashion, wild-type or catalytically impaired ACE2 has also been investigated as a potential therapeutic biologic that might interfere with the infection cycle of ACE2-targeting coronaviruses (Lei et al., 2020; Monteil et al., 2020)."}